ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
A 62-aa core of the cochlin LCCL domain induces macrophage M1 polarization in vitro.
Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Brain defence by the extracellular matrix protein Cochlin.Communications biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCochlin, encoded by the COCH gene, mediates innate immunity against bacterial infections by segregating pathogens and recruiting immune cells through its N-terminal LCCL domain. This domain is cleaved and secreted to attract macrophages and neutrophils, but its core motif has remained unclear.
methodsWe designed and synthesized a shortened core peptide of the LCCL domain (cLCCL; 62 amino acids) preserving the conserved structural motif. Structural stability was predicted by in silico modeling. The immunomodulatory effects of LCCL and cLCCL were evaluated in RAW264.7 macrophage cells using bulk RNA sequencing, quantitative PCR, Western blotting, flow cytometry, and immunocytochemistry.
resultsRNA sequencing in RAW264.7 cells showed that both LCCL and synthetic cLCCL peptides induced M1 polarization, with upregulation of TICAM2, CD40, and CD86. Flow cytometry demonstrated a significant increase in CD40(+)/CD86(+) M1-polarized macrophages following LCCL or cLCCL treatment, with comparable effects between the full-length and core peptides.
conclusionThe identified cLCCL appears to promote pro-inflammatory macrophage polarization, activate pro-inflammatory innate immune pathways, and warrants further evaluation in mechanistic and in vivo studies.
Indexed as
Identifiers
41803274What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.